The industry heavyweight behind Novavax’s push to bounce back

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

By Alexandra Pecci • March 25, 2025

How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

By Amy Baxter • March 17, 2025

Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

By Michael Gibney • March 13, 2025

How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?

With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.

By Amy Baxter • March 7, 2025

How pharma CEO pay shifted for these 4 companies last year

Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.

By Amy Baxter • March 3, 2025

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

By Michael Gibney • Feb. 27, 2025

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

By Ned Pagliarulo • Feb. 25, 2025

Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

By Alexandra Pecci • Feb. 25, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms

Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.

By Amy Baxter • Feb. 24, 2025

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

By Michael Gibney • Feb. 20, 2025

Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.

By Michael Gibney • Feb. 13, 2025

With uncertainty roiling Big Pharma, execs are placing lower-risk bets

The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.

By Michael Gibney • Feb. 6, 2025

RFK Jr. will face these critical tests if confirmed as head of the HHS

After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.

By Amy Baxter • Feb. 5, 2025

Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid

As President Trump and his cohorts plan to shut down the U.S. Agency for International Development, here’s what that could mean for global health and the drugmaking industry.

By Michael Gibney • Feb. 4, 2025

Pharma’s forecast for 2025: Sowing seeds of a rebound

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

By Meagan Parrish • Jan. 31, 2025

RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing

“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.

By Michael Gibney • Jan. 30, 2025

Executive hiring changes reflect a broader biotech comeback

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

By Alexandra Pecci • Jan. 29, 2025

Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt

As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.

By Michael Gibney • Jan. 28, 2025

Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

There’s more to pharma's regulatory story in 2025 than just the IRA.

By Meagan Parrish • Jan. 17, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Coming changes that could impact pharma from drug development to launch.

By Meagan Parrish • Jan. 10, 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.

By Michael Gibney • Jan. 9, 2025

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

By Meagan Parrish • Dec. 20, 2024

Will the ‘anti-woke’ movement derail DEI efforts in pharma?

Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.

By Meagan Parrish • Dec. 13, 2024